IP Library Granted Patent US 11,944,654
Granted Patent B2
US 11,944,654 · App. 17/886,274 · Granted Apr 2, 2024

Bacteriotherapy for clostridium difficile colitis

Inventor: Edwin J. Hlavka (Minneapolis, MN)
Assignee: Rebiotix, Inc.
A61K35/741A61K9/20A61K35/74C12N1/04C12N1/20G01N33/56911G01N2333/33G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,944,654
App. No.
17/886,274
Granted
Apr 2, 2024
Kind
B2
Abstract

This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut microbiota.

Claims (19)

1. An oral pharmaceutical composition, comprising:

a homogenized and filtered donor fecal sample; and

a cryoprotectant,

wherein the composition is disposed within an oral tablet or ingestible capsule.

2. The composition of claim 1 , wherein the composition is disposed within an oral tablet.

3. The composition of claim 1 , wherein the composition is disposed within an ingestible capsule.

4. The composition of claim 1 , wherein the oral table or ingestible capsule has an enteric coating.

5. The composition of claim 1 , wherein the cryoprotectant comprises a glycol.

6. An oral A pharmaceutical composition, comprising:

a homogenized and filtered donor fecal sample; and

a cryoprotectant.

7. The composition of claim 6 , wherein the cryoprotectant comprises a glycol.

8. The composition of claim 6 , wherein the cryoprotectant comprises glycerol.

9. A pharmaceutical composition, comprising:

a homogenized and filtered donor fecal sample; and

a cryoprotectant,

wherein the composition is provided in a patient-deliverable form.

10. The composition of claim 9 , wherein the patient deliverable form comprises a sterile delivery container.

11. The composition of claim 9 , wherein the patient deliverable form comprises a bag.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE INVENTOR EDWIN J. HLAVKA'S EXECUTION DATE FROM 03/13/2023 TO 03/13/2013 PREVIOUSLY RECORDED ON REEL 66407 FRAME 291. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 11, 2025
From: HLAVKA, EDWIN J.
To: MIKROBEX INC.
Reel/Frame 071514/0240 →
CHANGE OF NAME Recorded Jan 27, 2025
From: REBIOTIX INC.
To: FERRING MICROBIOME INC.
Reel/Frame 070022/0505 →
CHANGE OF NAME Recorded Feb 8, 2024
From: MIKROBEX INC.
To: REBIOTIX INC.
Reel/Frame 066541/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2024
From: HLAVKA, EDWIN J.
To: MIKROBEX INC.
Reel/Frame 066407/0291 →
Continuity (7)
Continuation 15964228 · Apr 27, 2018
Continuation 15251725 · Aug 30, 2016
Continuation 14093913 · Dec 2, 2013
Continuation 13576573
Provisional Application 61351184 · Jun 3, 2010
Provisional Application 61337283 · Feb 1, 2010
Related Publication 20230076826A1 · Mar 9, 2023